Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions remain.
The study utilized a multilabel segmentation algorithm that achieved high ... of diffusion-weighted MRI to assess early treatment responses in patients with newly diagnosed multiple myeloma.
This important study uses diffusion magnetic resonance imaging ... Given that much of our analyses relied on high-resolution dMRI data obtained with optimized sequences on 7T MRI machines (Vu et al., ...
One of the biggest risk is probably aging, myeloma is more common as people grow older. So the median age at which patients get diagnosed with myeloma is about 68/69 years. So it's still predominantly ...
A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...
People with multiple myeloma have high levels of certain proteins in their blood and urine. An oncologist (a medical doctor specialized in diagnosing and treating cancer) will test for and ...
So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.
During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...
Multiple myeloma starts in the plasma cells inside your bone marrow. People with multiple myeloma have high levels of certain proteins in their blood and urine. An oncologist (a medical doctor ...
Recovery from multiple myeloma leads to a renewed sense of purpose and determination ... As I belted out "Moon River," memories of playing it on my clarinet in high school flooded back. When I sang ...
Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...